BACKGROUND: The long-term efficacy of @entity4836 , a reversible @entity16374 cholinesterase inhibitor, in the treatment of postural @entity591 (POTS) @entity1 remains unclear. We report our retrospective, single-center, long-term experience regarding the efficacy and adverse effect profile of @entity4836 in the treatment of POTS @entity1 . METHODS: This retrospective study included an extensive review of electronic charts and data collection in regards to @entity1 demographics, orthostatic parameters, side-effect profile, subjective response to therapy, as well as laboratory studies recorded at each follow-up visit to our institution's @entity1163 and Autonomic Disorders Center. The response to @entity4836 therapy was considered successful if @entity1 had both symptom relief in addition to an objective response in orthostatic hemodynamic parameters (heart rate [HR] and blood pressure). Three hundred @entity1 with POTS were screened for evaluation in this study. Of these 300, 203 @entity1 with POTS who received @entity4836 therapy were reviewed. Of these 203 @entity1 , 168 were able to tolerate the medication after careful dose titration. The mean follow-up duration in this group of @entity1 was 12    3 (9-15) months. @entity4836 improved symptoms of orthostatic intolerance in 88 of 203 (43%) of total @entity1 or 88 of 172 (51%) who were able to tolerate the drug. The symptoms that improved the most included @entity1295 (55%), palpitations (60%), @entity1163 (60%), and @entity1163 (48%). Symptom reduction correlated with a statistically significant improvement in upright HR and diastolic blood pressure after treatment with @entity4836 as compared to their baseline hemodynamic parameters (standing HR 94    19 vs 82    16, P < 0.003, standing diastolic blood pressure 71    11 vs 74    12, P < 0.02). Gastrointestinal problems were the most common adverse effects (n = 39, 19%) reported. The overall efficacy of @entity4836 in our study was seen in 42% of total @entity1 or 52% of @entity1 who could tolerate taking the drug. CONCLUSION: The subgroup of POTS @entity1 who can tolerate oral @entity4836 may demonstrate improvement in their standing HR, standing diastolic blood pressure, and clinical symptoms of orthostatic intolerance.

XXXX in the treatment of postural @entity591 : a single-center experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity4836 :: ('MESH:D011729', 'Chemical') :: ['pyridostigmine', 'Pyridostigmine'] @entity16374 :: ('CHEBI:40574', 'Chemical') :: ['acetyl'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity1163 :: ('MESH:D013575', 'Disease') :: ['presyncope', 'syncope', 'Syncope'] @entity591 :: ('MESH:D013610', 'Disease') :: ['orthostatic tachycardia syndrome']
@entity4836 :: (MESH:D011729,Chemical) :: ['Pyridostigmine']
